ATE406899T1 - Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen - Google Patents

Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen

Info

Publication number: ATE406899T1
Authority: AT; Austria
Prior art keywords: endopeptidase; hsep; nep; prophylaxis; treatment
Prior art date: 2004-01-12

Application number

AT05701469T

Other languages

English (en)

Inventor

Michael Weske

Lechoslaw A Turski

Hrissanthi Ikonomidou

Dieter Ziegler

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-12

Filing date

2005-01-10

Publication date

2008-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34796705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406899(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-01-10 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406899T1 publication Critical patent/ATE406899T1/de

Links

102000003729 Neprilysin Human genes 0.000 title abstract 4
108090000028 Neprilysin Proteins 0.000 title abstract 4
102000005593 Endopeptidases Human genes 0.000 title abstract 2
108010059378 Endopeptidases Proteins 0.000 title abstract 2
208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
238000011321 prophylaxis Methods 0.000 title abstract 2
238000011282 treatment Methods 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 abstract 1
DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical class N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 abstract 1
QJJDBWAEIBNZPQ-UHFFFAOYSA-N 2-(3h-1,2-benzothiazepin-2-yl)acetic acid Chemical class S1N(CC(=O)O)CC=CC2=CC=CC=C21 QJJDBWAEIBNZPQ-UHFFFAOYSA-N 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
-1 phosphono-substituted benzazepinone Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

AT05701469T 2004-01-12 2005-01-10 Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen ATE406899T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53553804P	2004-01-12	2004-01-12
EP04100067		2004-01-12

Publications (1)

Publication Number	Publication Date
ATE406899T1 true ATE406899T1 (de)	2008-09-15

Family

ID=34796705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05701469T ATE406899T1 (de)	2004-01-12	2005-01-10	Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen

Country Status (22)

Country	Link
EP (1)	EP1706121B1 (de)
JP (1)	JP4951350B2 (de)
KR (1)	KR101219580B1 (de)
CN (1)	CN101076339B (de)
AT (1)	ATE406899T1 (de)
AU (1)	AU2005205067B2 (de)
BR (1)	BRPI0506750A (de)
CA (1)	CA2551789C (de)
CY (1)	CY1108588T1 (de)
DE (1)	DE602005009487D1 (de)
DK (1)	DK1706121T3 (de)
ES (1)	ES2313279T3 (de)
HR (1)	HRP20080611T3 (de)
IL (1)	IL176456A (de)
NO (1)	NO20063623L (de)
PL (1)	PL1706121T3 (de)
PT (1)	PT1706121E (de)
RU (1)	RU2362563C2 (de)
SI (1)	SI1706121T1 (de)
UA (1)	UA82008C2 (de)
WO (1)	WO2005067937A1 (de)
ZA (1)	ZA200605549B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2750510A1 (en) *	2009-01-24	2010-07-29	Phytopharm Plc	Treatment of neurotrophic factor mediated disorders
AR079059A1 (es)	2009-12-07	2011-12-21	Abbott Healthcare Products Bv	Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN106065006B (zh) *	2015-04-22	2020-06-05	深圳信立泰药业股份有限公司	一种中性内肽酶抑制剂盐晶型及其制备方法
PL424453A1 (pl)	2018-01-31	2019-08-12	Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością	Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) *	2018-01-31	2019-08-12	Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
CN110590695B (zh) *	2019-10-22	2023-03-21	南华大学	苯并氮杂环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19510566A1 (de) *	1995-03-23	1996-09-26	Kali Chemie Pharma Gmbh	Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) *	1997-11-12	1999-05-20	Solvay Pharm Gmbh	Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SK15812000A3 (sk) *	1998-04-23	2001-03-12	Novartis Ag	Inhibítory enzýmu na premenu endotelínu
US20020013307A1 (en) *	2000-05-23	2002-01-31	Pablo Lapuerta	Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6505135B2 (en) *	2001-03-13	2003-01-07	Micro Motion, Inc.	Initialization algorithm for drive control in a coriolis flowmeter
SK14102003A3 (sk) *	2001-05-18	2004-08-03	Solvay Pharmaceuticals Gmbh	Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv
CL2004000545A1 (es) *	2003-03-18	2005-01-28	Pharmacia Corp Sa Organizada B	Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

2005
- 2005-01-10 PL PL05701469T patent/PL1706121T3/pl unknown
- 2005-01-10 CA CA2551789A patent/CA2551789C/en not_active Expired - Fee Related
- 2005-01-10 SI SI200530457T patent/SI1706121T1/sl unknown
- 2005-01-10 DK DK05701469T patent/DK1706121T3/da active
- 2005-01-10 ES ES05701469T patent/ES2313279T3/es not_active Expired - Lifetime
- 2005-01-10 RU RU2006129288/15A patent/RU2362563C2/ru active
- 2005-01-10 WO PCT/EP2005/050075 patent/WO2005067937A1/de not_active Ceased
- 2005-01-10 CN CN2005800022847A patent/CN101076339B/zh not_active Expired - Fee Related
- 2005-01-10 PT PT05701469T patent/PT1706121E/pt unknown
- 2005-01-10 HR HR20080611T patent/HRP20080611T3/xx unknown
- 2005-01-10 BR BRPI0506750-2A patent/BRPI0506750A/pt not_active Application Discontinuation
- 2005-01-10 AU AU2005205067A patent/AU2005205067B2/en not_active Ceased
- 2005-01-10 DE DE602005009487T patent/DE602005009487D1/de not_active Expired - Lifetime
- 2005-01-10 AT AT05701469T patent/ATE406899T1/de active
- 2005-01-10 JP JP2006548311A patent/JP4951350B2/ja not_active Expired - Fee Related
- 2005-01-10 EP EP05701469A patent/EP1706121B1/de not_active Expired - Lifetime
- 2005-10-01 UA UAA200609032A patent/UA82008C2/uk unknown
2006
- 2006-06-21 IL IL176456A patent/IL176456A/en active IP Right Grant
- 2006-07-05 ZA ZA200605549A patent/ZA200605549B/xx unknown
- 2006-08-10 NO NO20063623A patent/NO20063623L/no not_active Application Discontinuation
- 2006-08-11 KR KR1020067016297A patent/KR101219580B1/ko not_active Expired - Fee Related
2008
- 2008-11-24 CY CY20081101348T patent/CY1108588T1/el unknown

Also Published As

Publication number	Publication date
PL1706121T3 (pl)	2009-02-27
HRP20080611T3 (hr)	2008-12-31
DE602005009487D1 (de)	2008-10-16
ZA200605549B (en)	2007-12-27
SI1706121T1 (sl)	2009-02-28
RU2006129288A (ru)	2008-02-20
KR101219580B1 (ko)	2013-01-08
EP1706121B1 (de)	2008-09-03
PT1706121E (pt)	2008-12-04
EP1706121A1 (de)	2006-10-04
CA2551789C (en)	2011-05-03
IL176456A (en)	2010-03-28
CN101076339A (zh)	2007-11-21
NO20063623L (no)	2006-10-12
RU2362563C2 (ru)	2009-07-27
UA82008C2 (uk)	2008-02-25
CY1108588T1 (el)	2014-04-09
AU2005205067B2 (en)	2009-10-22
CN101076339B (zh)	2011-02-09
BRPI0506750A (pt)	2007-05-22
JP4951350B2 (ja)	2012-06-13
ES2313279T3 (es)	2009-03-01
CA2551789A1 (en)	2005-07-28
AU2005205067A1 (en)	2005-07-28
DK1706121T3 (da)	2009-01-05
KR20060123541A (ko)	2006-12-01
WO2005067937A1 (de)	2005-07-28
IL176456A0 (en)	2006-10-05
JP2007517834A (ja)	2007-07-05

Similar Documents

Publication	Publication Date	Title
MX2012001985A (es)	2012-02-29	Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
NO20060324L (no)	2006-05-18	[1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
GEP20125565B (en)	2012-07-10	Lactam compounds and their pharmaceutical use
UA103272C2 (uk)	2013-09-25	2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
UA83899C2 (uk)	2008-08-26	Сполуки імідазолу для лікування нейродегенеративних розладів
MA27305A1 (fr)	2005-05-02	Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
NO20092342L (no)	2009-07-02	Azaspiroderivativater
ATE388708T1 (de)	2008-03-15	Piperazinderivate und anwendungsverfahren
MY147677A (en)	2012-12-31	Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
CR9622A (es)	2008-04-10	Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
CY1108588T1 (el)	2014-04-09	ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ
IL176546A0 (en)	2006-10-31	Imidazoline derivatives having cb1-antagonistic activity
TW200604196A (en)	2006-02-01	New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2008036316A3 (en)	2008-11-06	Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200602297A (en)	2006-01-16	Sulfonamide compounds for the treatment of neurodegenerative disorders
ATE402150T1 (de)	2008-08-15	Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
WO2005097114A3 (en)	2006-08-24	Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
WO2007034326A3 (en)	2007-08-30	Imidazole compounds for the treatment of neurological disorders
TH126304A (th)	2013-08-19	สารยับยั้งของนิวตราลเอนโดเพปติเดส (Neutral Endopeptidase) (NEP) และของเอนโดเพปติเดส (Endopeptidase) ที่ละลายของคน (hSEP) สำหรับป้องกันและรักษาความผิดปกติที่เป็นการเสื่อมสลายของประสาท
ATE453638T1 (de)	2010-01-15	Amidinderivate von 2-heteroarylchinazolinen und chinolinen; wirksame analgetika und entzündungshemmende mittel
DE60312154D1 (de)	2007-04-12	2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
WO2005095361A8 (en)	2006-08-03	Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
UA84737C2 (ru)	2008-11-25	Производные имидазолина с антагонистической активностью относительно cb1
TW200621255A (en)	2006-07-01	Novel compounds

Legal Events

Date

Code

Title

Description

2009-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1706121

Country of ref document: EP